retatrutide autoimmune disease Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished What To Know About Buying

A minority of its patients are using compounded semaglutide

Williams, S.T., et al

Fewer GI side effects

Glycemic control changes typically occur within days to weeks after stopping GLP-1 therapy

180+ Published studies, including 40+ randomized controlled trials 35+ Years of serving organizations across all industries and budgets #1 Doctor-recommended program for weight loss* Weight health that works for your organization The Weight Watchers comprehensive platform is built to help your people and your organization achieve weight health goals by providing comprehensive clinical services and scalable support every step of the way

Data are presented as a percentage of MTP protein expression versus the loading control GAPDH ( n = 3)